{
    "pmcid": "9734137",
    "summary": "The paper titled \"A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration\" presents a comprehensive study on the development and characterization of a bispecific nanobody dimer, 2-3-Fc, designed to neutralize SARS-CoV-1 and SARS-CoV-2 variants, including the challenging Omicron subvariants. Here is a detailed summary focusing on the insights related to nanobodies in the context of SARS-CoV-2 nanobody binder design:\n\n### Key Insights on Nanobodies:\n\n1. **Nanobody Characteristics**:\n   - Nanobodies (Nbs), or VHHs, are single-domain antibodies derived from camelids. They are smaller and structurally simpler than conventional antibodies, consisting of only one Ig domain.\n   - Nbs are advantageous due to their ease of engineering into multivalent formats, thermal resistance, and stability under harsh conditions, making them suitable for storage and transportation during pandemics.\n\n2. **Nanobody Engineering**:\n   - The study highlights the engineering of a bispecific nanobody dimer, 2-3-Fc, which combines two distinct nanobodies: aSA3 and aRBD-2. This design leverages the non-overlapping binding sites of the two nanobodies on the receptor-binding domain (RBD) of the virus.\n   - Multivalent engineering, such as the creation of bispecific nanobodies, enhances binding avidity and neutralization potency, offering a cost-effective alternative to antibody cocktails.\n\n3. **Discovery and Characterization of aSA3**:\n   - aSA3 is a newly identified nanobody that targets a conserved epitope on the RBD core, distinct from the receptor-binding motif (RBM) targeted by aRBD-2. It shows strong cross-reactivity with SARS-CoV-1 and wild-type SARS-CoV-2.\n   - The crystal structure of aSA3 bound to the SARS-CoV-1 RBD reveals its binding mechanism, which involves key residues that are conserved across SARS-CoV-1 and SARS-CoV-2, explaining its broad neutralization capability.\n\n4. **Development of 2-3-Fc**:\n   - The bispecific nanobody dimer, 2-3-Fc, was engineered by fusing aSA3-Fc to aRBD-2, targeting distinct epitopes on the RBD. This design allows simultaneous binding to the same or adjacent RBDs on the spike protein, enhancing neutralization potency.\n   - 2-3-Fc demonstrates high neutralizing potency against all major SARS-CoV-2 variants of concern, including Omicron subvariants BA.1, BA.2, and BA.5, with single-digit ng/mL IC50 values.\n\n5. **In Vivo Efficacy**:\n   - In hamster models, 2-3-Fc administered intraperitoneally at 10 mg/kg provided substantial protection against Omicron infection. Notably, low-dose intranasal administration (0.5 mg/kg) was highly effective, completely eliminating infectious particles in the respiratory tract.\n   - Intranasal delivery is highlighted as a promising non-invasive method for prophylactic administration, potentially offering a practical approach for widespread use in preventing SARS-CoV-2 infection.\n\n6. **Adaptation to Emerging Variants**:\n   - The study addresses the challenge of emerging variants, such as BA.2.75, by introducing a Y29G mutation in aRBD-2, resulting in the derivative 2(Y29G)-3-Fc. This modification restores binding and enhances neutralization potency against the BA.2.75 variant.\n   - The structural insights and strategic mutations ensure that the engineered nanobodies maintain efficacy across a broad range of variants, including those with mutations that might otherwise confer resistance.\n\n7. **Potential Therapeutic and Prophylactic Applications**:\n   - The bispecific nanobody dimer 2-3-Fc, and its derivative 2(Y29G)-3-Fc, are positioned as potential therapeutic and prophylactic candidates against SARS-CoV-1, SARS-CoV-2, and their variants.\n   - The study suggests that these nanobodies could complement vaccines, particularly for high-risk populations, offering a robust tool for pandemic preparedness and response.\n\nIn summary, the paper underscores the potential of nanobody engineering in developing broad-spectrum neutralizing agents against SARS-CoV-2 and its variants. The bispecific nanobody dimer 2-3-Fc exemplifies how structural insights and strategic design can lead to potent, versatile, and practical therapeutic candidates for combating current and future coronavirus threats.",
    "title": "A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration"
}